In summary, we propose that CBX7-AKT-NF-κB-miR-21 pathway is an important determinant of GCSC phenotype and that targeting this pathway may provide new therapeutic opportunities for gastric cancer treatment. This evidence concerns the gene CBX7 and gastric cancer.